<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Piperacillin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Piperacillin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Piperacillin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11248" href="/d/html/11248.html" rel="external">see "Piperacillin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F210349"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F210309"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b>
<b>IM, IV:</b> Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5291731-7ad7-4972-a812-4cdce3bcc853">Severe infections including gynecologic, intra-abdominal, hospital-acquired/ventilator-associated pneumonia, bloodstream, and skin/soft tissue</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe infections including gynecologic, intra-abdominal, hospital-acquired/ventilator-associated pneumonia, bloodstream, and skin/soft tissue: IV:</b> Usual dosage: 12 to 18 g daily (200 to 300 mg/kg daily) in divided doses every 4 to 6 hours (maximum: 24 g daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78fb2394-499a-4d8d-80b7-607061938325">Urethritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urethritis (gonococcal, uncomplicated):</b>
<b>IM:</b> 2 g once (<b>Note:</b> Administer probenecid 30 minutes prior to piperacillin).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated: IV:</b> Usual dosage: 8 to 16 g daily (125 to 200 mg/kg daily) in divided doses every 6 to 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aef3665-b206-47be-ac86-180f5fa7d6b5">Urinary tract infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, uncomplicated:</b>
<b>IM, IV:</b> Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990800"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IV:</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;40 mL/minute or serum creatinine 1.5 to 3 mg/dL: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 20-40 mL/minute or serum creatinine 3.1 to 5 mg/dL:</p>
<p style="text-indent:-2em;margin-left:4em;">Urinary tract infection (uncomplicated): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Urinary tract infection (complicated): 3 g every 8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Severe systemic infection: 4 g every 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;20 mL/minute or serum creatinine &gt;5 mg/dL:</p>
<p style="text-indent:-2em;margin-left:4em;">Urinary tract infection (complicated/uncomplicated): 3 g every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Severe systemic infection: 4 g every 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Severe systemic infection: 2 g every 8 hours; administer 1 g supplemental dose after each dialysis session; dialyzable (30% to 50%)</p></div>
<div class="block doha drugH1Div" id="F50987996"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F210310"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Dosage adjustment may be necessary for renal impairment.</p></div>
<div class="block dop drugH1Div" id="F210331"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Not available in the United States. Piperacillin has been discontinued &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b> Children ≥12 years and Adolescents: IM, IV: Refer to adult dosing.</p></div>
<div class="block dorp drugH1Div" id="F51154215"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): <b>Note:</b> Dosage recommendations are based on the piperacillin component. Dosing based on a usual dose of 200 to 300 mg piperacillin kg/<b>day</b> in divided doses every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 8 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis (IHD): Removed by hemodialysis; dosing adjustment suggested</p></div>
<div class="block dohp drugH1Div" id="F51204760"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling; based on experience with piperacillin/tazobactam, no adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F210275"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Local thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Confusion, drowsiness, myoclonus, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Electrolyte disturbance, hypokalemia</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Abnormal platelet aggregation (high doses), agranulocytosis, hemolytic anemia, pancytopenia, positive direct Coombs test, prolonged prothrombin time (high doses)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Immunologic: Jarisch-Herxheimer reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Acute interstitial nephritis, acute renal failure</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F210291"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to any of the penicillins and/or cephalosporins or any component of the formulation; hypersensitivity to local anesthetics of the amide type (when reconstituted with lidocaine for IM use)</p></div>
<div class="block war drugH1Div" id="F210272"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients. Discontinue if hypersensitivity occurs; initiate appropriate rescue treatment for serious hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Bleeding disorders: Particularly in patients with renal impairment, bleeding disorders have been observed; discontinue if thrombocytopenia or bleeding occurs.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Leukopenia/neutropenia: During prolonged use, leukopenia and neutropenia have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Use with caution particularly in sodium-restricted patients receiving prolonged therapy; formulation contains 42.5 mg of sodium per gram. Monitor electrolyte status and cardiac function with prolonged therapy.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cystic fibrosis: An increased frequency of fever and rash has been reported in patients with cystic fibrosis.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Infectious mononucleosis: Patients with infectious mononucleosis have developed rash during therapy with other penicillins (eg, ampicillin, amoxicillin).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment, due to sodium load and adverse effects (hematologic, neuropsychological changes); dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Seizure disorders: High drug levels, particularly in the presence of renal impairment, may increase risk of seizures. Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Syphilis: Symptoms of syphilis may be masked or delayed in patients receiving high-dose antimicrobial treatment of gonorrhea; patients with gonorrhea should be evaluated for syphilis prior to initiating antimicrobial treatment and if syphilis is suspected, continue serologic testing monthly for at least 4 months.</p></div>
<div class="block prod-avail drugH1Div" id="F23325456"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F55989120"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52867950"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g ([DSC]); 3 g ([DSC]); 4 g ([DSC])</p></div>
<div class="block adm drugH1Div" id="F210288"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Rapid administration can lead to seizures. Administer by IV injection over 3 to 5 minutes or by intermittent infusion over 20 minutes to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: IM injection should be administered into the upper outer quadrant of the buttocks. Do not administer more than 2 g per IM injection site.</p></div>
<div class="block admp drugH1Div" id="F52613597"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer into the upper outer quadrant of the buttocks (gluteus maximus). Do not administer more than 2 g per injection site.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Bolus: Administer slow IV over 3 to 5 minutes to avoid vein irritation. Rapid administration can lead to seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent infusion: Administer over 20 to 30 minutes; however, longer infusion times (eg, 2 hours) may be used.</p></div>
<div class="block use drugH1Div" id="F210287"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infection: </b>Treatment of infection caused by susceptible gram-negative/gram-positive aerobic and anaerobic bacteria, including intra-abdominal infection, bloodstream infection, lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, gynecological infection, urinary tract infection (complicated and uncomplicated), and urethritis (uncomplicated); may also be used to treat mixed infections due to susceptible streptococci.</p></div>
<div class="block cyt drugH1Div" id="F13299883"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Inhibits</b> OAT1/3</p></div>
<div class="block dri drugH1Div" id="F210277"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: Piperacillin may increase the serum concentration of Flucloxacillin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: Piperacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vecuronium: Piperacillin may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5719723"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Piperacillin crosses the placenta and distributes into the amniotic fluid (Brown 1990; Heikkilä 1991).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of piperacillin may be altered. At term, the apparent volume of distribution of piperacillin is increased and peak concentrations are significantly lower. Total clearance is normal to increased at term (Heikkilä 1991; Voight 1985). These changes continue into the early postpartum period (Charles 1985; Martens 1987).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p>
<p style="text-indent:0em;margin-top:2em;">Antibiotic prophylaxis with piperacillin may be appropriate for the prevention of endocarditis for patients undergoing obstetric and gynecologic procedures (consult current recommendations) (SOGC [Van Eyk 2018]; SOGC [van Schalkwyk 2017]).</p></div>
<div class="block brc drugH1Div" id="F5707585"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Piperacillin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer reports small amounts of piperacillin are present in breast milk and recommends that caution be exercised when administering piperacillin to nursing women. In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F210294"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Sodium content of 1 g: 1.85 mEq (42.5 mg)</p></div>
<div class="block mop drugH1Div" id="F210282"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for signs and symptoms of anaphylaxis during first dose; with extended therapy consider monitoring of electrolytes and cardiac status (patients with impaired cardiac function), serum creatinine, BUN, hepatic function, and CBC.</p></div>
<div class="block pha drugH1Div" id="F210271"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F210290"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~16% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination (dose dependent; prolonged with renal impairment): Adults: ~1 hour (decreased in patients with cystic fibrosis)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: IM: 30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; partially feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038768"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Piperacilina richet | Pipril</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Geng xin | Piperacillin | Wei Yi Wang</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pipraks | Pipril</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ab-piperacillin | Piperacillin | Piperacillin Actavis | Piperacillin eberth | Piperacillin hexal | Piperacillin hikma | Piperacillin Ibisqus</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ivacin | Piperacillin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Piperacilline dakota | Piperacilline G Gam | Piperacilline panpharma | Piperilline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ledercil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pipracin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Pipracil | Piprapen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cilpier | Diperil | Ecosette | Farecillin | Peracil | Perasint | Picillin | Piperacillina | Piperacillina doc | Piperacillina drm | Piperacillina eg | Piperacillina K24 | Piperacillina sandoz | Piperacillina Sigma tau | Piperital | Pipersal | Pipertex | Reparcillin | Semipenil | Viracillina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alukabemin | Alukabemin towa | Bicphenin | Hishiyachlorin | Homosullin | Penmalin | Penmalin sawai | Pentcillin | Piciliant | Piperacillin na | Piperacillin sodium nichiiko | Pipeyuncin | Planjin | Taiperacilin chemiphar | Taiperacilin kowa | Taiperacilin taiyo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acopex | Dongkoo piperacillin | Jeil piperacillin sodium | Penmix piperacillin | Peracillin | Piperacillin | Piperacin | Widecillin | Yuhan piperacillin sodium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isipen | Piprax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Isipen | Piperacillin | Piprax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pipracil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pipcil | Piperacilline</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin | Pipril</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Isipen | Piperacillin | Pipril</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin | Pipracil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fidelbiotico</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Picillin | Pipracil | Piprax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Peracin | Pipracil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Piperacillin usp | Piperal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Piprax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Peracillin | Picillina | Piperacillin | Pipril | Pitamycin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Pipril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sabax-piperacillin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al; The National Birth Defects Prevention Study. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol.</i> 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2119561">
<a name="2119561"></a>Brown CE, Christmas JT, and Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. <i>Am J Obstet Gynecol</i>. 1990;163(3):938-943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2119561/pubmed" id="2119561" target="_blank">2119561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4085922">
<a name="4085922"></a>Charles D, Larsen B. Pharmacokinetics of piperacillin in the postpartum patient. <i>Gynecol Obstet Invest</i>. 1985;20(4):194-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/4085922/pubmed" id="4085922" target="_blank">4085922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med.</i> 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol.</i> 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11549103">
<a name="11549103"></a>Dowell JA, Korth-Bradley J, Milisci M, et al, "Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment," <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/11549103/pubmed" id="11549103" target="_blank">11549103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7263563">
<a name="7263563"></a>Farchione LA, "Inactivation of Aminoglycosides by Penicillins," <i>J Antimicrob Chemother</i>, 1981, 8(Suppl A):27-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7263563/pubmed" id="7263563" target="_blank">7263563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2014975">
<a name="2014975"></a>Fuchs PC, Stickel S, Anderson PH, et al, "<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations," <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2014975/pubmed" id="2014975" target="_blank">2014975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1416875">
<a name="1416875"></a>Halstenson CE, Wong MO, Herman CS, et al, "Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease," <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1416875/pubmed" id="1416875" target="_blank">1416875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1960122">
<a name="1960122"></a>Heikkilä A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. <i>J Antimicrob Chemother</i>. 1991; 28(3):419-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1960122/pubmed" id="1960122" target="_blank">1960122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9408514">
<a name="9408514"></a>Hitt CM, Patel KB, Nicolau DP, et al, "Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily," <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/9408514/pubmed" id="9408514" target="_blank">9408514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6223576">
<a name="6223576"></a>Konishi H, Goto M, Nakamoto Y, et al, "Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin," <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6223576/pubmed" id="6223576" target="_blank">6223576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf.</i> 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6651279">
<a name="6651279"></a>Lau A, Lee M, Flascha S, et al, "Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function," <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6651279/pubmed" id="6651279" target="_blank">6651279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3439808">
<a name="3439808"></a>Martens MG, Faro S, Feldman S, et al. Pharmacokinetics of the acyclureidopenicillins piperacillin and mezlocillin in the postpartum patient. <i>Antimicrob Agents Chemother</i>. 1987; 31(12):2015-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3439808/pubmed" id="3439808" target="_blank">3439808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol.</i> 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Piperacillin [product monograph]. Kirkland, Quebec, Canada: Hospira Healthcare Corporation; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7237864">
<a name="7237864"></a>Russoe ME and Atkins-Thor E, "Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate," <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7237864/pubmed" id="7237864" target="_blank">7237864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7791416">
<a name="7791416"></a>Tan JS and File TM Jr, “Antipseudomonal Penicillins,” <i>Med Clin North Am</i>, 1995, 79(4):679-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7791416/pubmed" id="7791416" target="_blank">7791416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6462107">
<a name="6462107"></a>Thompson MIB, Russo ME, Saxon BJ, et al, "Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease," <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6462107/pubmed" id="6462107" target="_blank">6462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30390951">
<a name="30390951"></a>Van Eyk N, van Schalkwyk J. No. 275-antibiotic prophylaxis in gynaecologic procedures.<i> J Obstet Gynaecol Can</i>. 2018;40(10):e723-e733. doi:10.1016/j.jogc.2018.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/30390951/pubmed" id="30390951" target="_blank">30390951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28859772">
<a name="28859772"></a>van Schalkwyk J, Van Eyk N. No. 247-antibiotic prophylaxis in obstetric procedures. <i>J Obstet Gynaecol Can.</i> 2017;39(9):e293-e299. doi: 10.1016/j.jogc.2017.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/28859772/pubmed" id="28859772" target="_blank">28859772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4008387">
<a name="4008387"></a>Viollier AF, Standiford HC, Drusano GL, et al, "Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin," <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/4008387/pubmed" id="4008387" target="_blank">4008387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3908007">
<a name="3908007"></a>Voigt R, Schröder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. <i>Chemotherapy</i>. 1985;31(6):417-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3908007/pubmed" id="3908007" target="_blank">3908007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1952861">
<a name="1952861"></a>Walterspiel JN, Feldman S, Van R, et al, "Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin," <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1952861/pubmed" id="1952861" target="_blank">1952861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002. Accessed June 3, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ, “The Penicillins,” <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2254575">
<a name="2254575"></a>Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2254575/pubmed" id="2254575" target="_blank">2254575</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9775 Version 159.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
